Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 147 No. 4142 (2017)

Evaluation of the National Skin Cancer Campaign: a Swiss experience of Euromelanoma

  • Sven Lieberherr
  • S. Morteza Seyed Jafari
  • Simone Cazzaniga
  • Enrica Bianchi
  • Bettina Schlagenhauff
  • Gion Tscharner
  • Jürg Hafner
  • Carlo Mainetti
  • Anne-Karine Lapointe
  • Robert E. Hunger
Cite this as:
Swiss Med Wkly. 2017;147:w14511



Skin cancer is a burden to healthcare and patients worldwide. The incidence of skin cancer has been rising during recent decades and this trend is expected to continue in the future. Numerous risk factors have been identified and prevention strategies developed. The Euromelanoma campaign is a pan-European skin cancer prevention programme, targeted to both primary and secondary prevention of malignant melanoma. The current study aimed to evaluate the results of the Swiss skin cancer screening day 2016.


A questionnaire was used to obtain data on characteristics and suspected skin cancers of all participants. Follow-up of patients with suspicious lesions was performed 3 to 6 months later.


During the campaign, 2795 people were screened. Of the screened individuals, 157 participants (58% female, 42% male; mean age 58.8 years) underwent further evaluations; 6 cutaneous malignant melanomas, 21 basal cell carcinomas and 2 squamous cell carcinomas were detected. Detection rates were 0.21% for cutaneous melanoma, 0.75% for basal cell carcinoma and 0.07% for squamous cell carcinoma.


Our study provides an up-to-date evaluation of the Swiss Euromelanoma campaign 2016. The results are mostly in line with data from other European studies. Considering the morbidity, mortality and financial and social impact of skin cancer, the capacity to raise awareness of risk factors, skin cancer prevention methods and educating high-risk and at-risk individuals, we may assume that a National Screening Day has a crucial impact on the public health system.


  1. Suppa M, Altomare G, Cannavò SP, Capizzi R, Catricalà C, Colombo E, et al.; Italian investigators for the Euromelanoma prevention campaign. The Italian Euromelanoma Day: evaluation of results and implications for future prevention campaigns. Int J Dermatol. 2014;53(6):699–706. doi:.
  2. Stratigos AJ, Forsea AM, van der Leest RJ, de Vries E, Nagore E, Bulliard JL, et al. Euromelanoma: a dermatology-led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future. Br J Dermatol. 2012;167(Suppl 2):99–104. doi:.
  3. van der Leest RJ, de Vries E, Bulliard JL, Paoli J, Peris K, Stratigos AJ, et al. The Euromelanoma skin cancer prevention campaign in Europe: characteristics and results of 2009 and 2010. J Eur Acad Dermatol Venereol. 2011;25(12):1455–65. doi:.
  4. Forsea AM, del Marmol V ; Euromelanoma Working Group. Impact, challenges and perspectives of Euromelanoma, a pan-European campaign of skin cancer prevention. J Eur Acad Dermatol Venereol. 2013;27(10):1317–9.
  5. Bulliard JL, Panizzon RG, Levi F. Prévention du métanome en Suisse: où en sommes-nous ? [Melanoma prevention in Switzerland: where do we stand?]. Rev Med Suisse. 2006;2(63):1122–5. Article in French.
  6. Hunger RE, Seyed Jafari SM, Angermeier S, Shafighi M. Excision of fascia in melanoma thicker than 2 mm: no evidence for improved clinical outcome. Br J Dermatol. 2014;171(6):1391–6. doi:.
  7. Bulliard JL, Maspoli M, Panizzon RG, Hohl D, Gueissaz F, Levi F. Evaluation of the Euromelanoma skin cancer screening campaign: the Swiss experience. J Eur Acad Dermatol Venereol. 2008;22(3):365–6. doi:.
  8. Suppa M, Neri L, Bianchi L, Capizzi R, Carbone A, Catricalà C, et al. The first skin cancer screening day at the Italian parliament: a Euromelanoma initiative. Int J Dermatol. 2015;54(1):42–9. doi:.
  9. Levi F, Te VC, Randimbison L, Erler G, La Vecchia C. Trends in skin cancer incidence in Vaud: an update, 1976-1998. Eur J Cancer Prev. 2001;10(4):371–3. doi:.
  10. Naldi L, Chatenoud L, Piccitto R, Colombo P, Placchesi EB, La Vecchia C ; Prevalence of Actinic Keratoses Italian Study (PraKtis) Group. Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: Results from the Prevalence of Actinic Keratoses Italian Study, 2003-2004. Arch Dermatol. 2006;142(6):722–6. doi:.
  11. Seyed Jafari SM, Jäckle P, Michel A, Angermeier S, Hunger R, Shafighi M. Prognostic value of sentinel lymph node biopsy in melanomas of different Breslow’s thickness. Swiss Med Wkly. 2016;146:w14358.
  12. Seidenari S, Benati E, Ponti G, Borsari S, Ferrari C, Albertini G, et al. Italian Euromelanoma Day Screening Campaign (2005-2007) and the planning of melanoma screening strategies. Eur J Cancer Prev. 2012;21(1):89–95. doi:.
  13. Geller AC, Zhang Z, Sober AJ, Halpern AC, Weinstock MA, Daniels S, et al. The first 15 years of the American Academy of Dermatology skin cancer screening programs: 1985-1999. J Am Acad Dermatol. 2003;48(1):34–41. doi:.
  14. Paoli J, Danielsson M, Wennberg AM. Results of the ‘Euromelanoma Day’ screening campaign in Sweden 2008. J Eur Acad Dermatol Venereol. 2009;23(11):1304–10. doi:.
  15. Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin. 2016;66(6):460–80. doi:.
  16. Wernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Blasi PR. Screening for Skin Cancer in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016;316(4):436–47. doi:.
  17. Geller AC, Greinert R, Sinclair C, Weinstock MA, Aitken J, Boniol M, et al. A nationwide population-based skin cancer screening in Germany: proceedings of the first meeting of the International Task Force on Skin Cancer Screening and Prevention (September 24 and 25, 2009). Cancer Epidemiol. 2010;34(3):355–8. doi:.
  18. Katalinic A, Waldmann A, Weinstock MA, Geller AC, Eisemann N, Greinert R, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. Cancer. 2012;118(21):5395–402. doi:.
  19. Katalinic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol. 2003;149(6):1200–6. doi:.
  20. Shellenberger R, Nabhan M, Kakaraparthi S. Melanoma screening: A plan for improving early detection. Ann Med. 2016;48(3):142–8. doi:.
  21. Boniol M, Autier P, Gandini S. Melanoma mortality following skin cancer screening in Germany. BMJ Open. 2015;5(9):e008158. doi:.
  22. Lakhani NA, Saraiya M, Thompson TD, King SC, Guy GP, Jr. Total body skin examination for skin cancer screening among U.S. adults from 2000 to 2010. Prev Med. 2014;61:75–80. doi:.
  23. Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review. Eur J Cancer Prev. 2015;24(2):141–9. doi:.

Most read articles by the same author(s)